The DOI matches its Crossref record.
Low-Molecular-Weight Peptidic and Cyclic Antagonists of the Receptor for the Complement Factor C5a
Open accessAbstract
Activation of the human complement system of plasma proteins during immunological host defense can result in overproduction of potent proinflammatory peptides such as the anaphylatoxin C5a. Excessive levels of C5a are associated with numerous immunoinflammatory diseases, but there is as yet no clinically available antagonist to regulate the effects of C5a. We now describe a series of small molecules derived from the C-terminus of C5a, some of which are the most potent low-molecular-weight C5a receptor antagonists reported to date for the human polymorphonuclear leukocyte (PMN) C5a receptor. 1H NMR spectroscopy was used to determine solution structures for two cyclic antagonists and to indicate that antagonism is related to a turn conformation, which can be stabilized in cyclic molecules that are preorganized for receptor binding. While several cyclic derivatives were of similar antagonistic potency, the most potent antagonist was a hexapeptide-derived macrocycle AcF[OPdChaWR] with an IC50 = 20 nM against a maximal concentration of C5a (100 nM) on intact human PMNs. Such potent C5a antagonists may be useful probes to investigate the role of C5a in host defenses and to develop therapeutic agents for the treatment of many currently intractable inflammatory conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hajishengallis, G., Liang, S., Payne, M. A., Hashim, A., Jotwani, R., Eskan, M. A., McIntosh, M. L., Alsam, A., Kirkwood, K. L., Lambris, J. D., et al. (2011) · Cell Host & Microbe · doi:10.1016/j.chom.2011.10.006 · Cited by 1,154
Modulation of the antitumor immune response by complement
Markiewski, M. M., DeAngelis, R. A., Benencia, F., Ricklin-Lichtsteiner, S. K., Koutoulaki, A., Gerard, C., Coukos, G., & Lambris, J. D. (2008) · Nature Immunology · doi:10.1038/ni.1655 · Cited by 778
Drusen complement components C3a and C5a promote choroidal neovascularization
Nozaki, M., Raisler, B. J., Sakurai, E., Sarma, J. V., Barnum, S. R., Lambris, J. D., Chen, Y., Zhang, K., Ambati, B. K., Baffi, J. Z., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408835103 · Cited by 650
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome
Girardi, G., Berman, J., Redecha, P., Spruce, L., Thurman, J. M., Kraus, D., Hollmann, T. J., Casali, P., Caroll, M. C., Wetsel, R. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318817 · Cited by 594
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome
Girardi, G., Berman, J., Redecha, P., Spruce, L., Thurman, J. M., Kraus, D., Hollmann, T. J., Casali, P., Caroll, M. C., Wetsel, R. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18817 · Cited by 575
Mollnes, T. E., Brekke, O., Fung, M. S. C., Fure, H., Christiansen, D., Bergseth, G., Videm, V., Lappegård, K. T., Köhl, J., & Lambris, J. D. (2002) · PubMed · doi:10.1182/blood.v100.5.1869.h81702001869_1869_1877 · Cited by 455
Orally Absorbed Cyclic Peptides
Nielsen, D. S., Shepherd, N. E., Xu, W., Lucke, A. J., Stoermer, M. J., & Fairlie, D. P. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00838 · Cited by 445
Self-citationThe proinflammatory mediators C3a and C5a are essential for liver regeneration
Strey, C. W., Markiewski, M., Mastellos, D., Tudoran, R., Spruce, L. A., Greenbaum, L. E., & Lambris, J. D. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030374 · Cited by 436
The role of complement in biomaterial-induced inflammation
Nilsson, B., Ekdahl, K. N., Mollnes, T. E., & Lambris, J. D. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.06.020 · Cited by 431
Constraining Cyclic Peptides To Mimic Protein Structure Motifs
Hill, T. A., Shepherd, N. E., Diness, F., & Fairlie, D. P. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201401058 · Cited by 418
Self-citationFunction, structure and therapeutic potential of complement C5a receptors
Monk, P. N., Scola, A., Madala, P., & Fairlie, D. P. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707332 · Cited by 404
Self-citationThe renaissance of complement therapeutics
Ricklin, D., Mastellos, D. C., Reis, E. S., & Lambris, J. D. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.156 · Cited by 379
Regulation of Toll-like receptor–mediated inflammatory response by complement in vivo
Zhang, X., Kimura, Y., Fang, C., Zhou, L., Sfyroera, G., Lambris, J. D., Wetsel, R. A., Miwa, T., & Song, W.-C. (2007) · Blood · doi:10.1182/blood-2006-12-063636 · Cited by 373
THE ROLE OF THE COMPLEMENT SYSTEM IN ISCHEMIA-REPERFUSION INJURY
Arumugam, T. V., Shiels, I. A., Woodruff, T. M., Granger, D. N., & Taylor, S. M. (2004) · Shock · doi:10.1097/00024382-200405000-00002 · Cited by 327
Self-citationInhibiting the C5–C5a receptor axis
Woodruff, T. M., Nandakumar, K. S., & Tedesco, F. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.04.014 · Cited by 289
Cholesterol Crystals Induce Complement-Dependent Inflammasome Activation and Cytokine Release
Samstad, E. O., Niyonzima, N., Nymo, S., Aune, M. H., Ryan, L., Bakke, S. S., Lappegård, K. T., Brekke, O.-L., Lambris, J. D., Damås, J. K., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302484 · Cited by 289
Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression
Corrales, L., Ajona, D., Rafail, S., Lasarte, J. J., Riezu-Boj, J. I., Lambris, J. D., Rouzaut, A., Pajares, M. J., Montuenga, L. M., & Pio, R. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201654 · Cited by 281
Inhibition of Protein−Protein Association by Small Molecules: Approaches and Progress
Toogood, P. L. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010468s · Cited by 281
Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans
Hillebrandt, S., Wasmuth, H. E., Weiskirchen, R., Hellerbrand, C., Keppeler, H., Werth, A., Schirin-Sokhan, R., Wilkens, G., Geier, A., Lorenzen, J., et al. (2005) · Nature Genetics · doi:10.1038/ng1599 · Cited by 258
Mastellos, D., Papadimitriou, J. C., Franchini, S., Tsonis, P. A., & Lambris, J. D. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2479 · Cited by 255
Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches
Brayden, D. J., Hill, T. A., Fairlie, D. P., Maher, S., & Mrsny, R. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.007 · Cited by 253
Self-citationComplement modulates the cutaneous microbiome and inflammatory milieu
Chehoud, C., Rafail, S., Tyldsley, A. S., Seykora, J. T., Lambris, J. D., & Grice, E. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307855110 · Cited by 184
Langer, H. F., Chung, K.-J., Orlova, V. V., Choi, E. Y., Kaul, S., Kruhlak, M. J., Alatsatianos, M., DeAngelis, R. A., Roche, P. A., Magotti, P., et al. (2010) · Blood · doi:10.1182/blood-2010-01-261503 · Cited by 176
Disruption of protein–protein interactions: Towards new targets for chemotherapy
Loregian, A., & Palù, G. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20356 · Cited by 108
Mangsbo, S. M., Sanchez, J., Anger, K., Lambris, J. D., Ekdahl, K. N., Loskog, A. S., Nilsson, B., & Tötterman, T. H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902374 · Cited by 42
Metadata
- Authors
- Finch, A. M., Wong, A. K., Paczkowski, N. J., Wadi, S. K., Craik, D. J., Fairlie, D. P., & Taylor, S. M.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1999-05-07
- Volume
- 42
- Issue
- 11
- Pages
- 1965-1974
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1970816982
- Cited by
- 246
- References
- 0
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.